TG Therapeutics Presents New Clinical Data Across Its Multiple Sclerosis Portfolio at MSToronto 2026
TG Therapeutics Highlights Seven-Year BRIUMVI Data, Positive Phase 3 ENHANCE Results and Progress in Progressive MS Research at MSToronto2026 TG Therapeutics, Inc. (NASDAQ: TGTX) has announced a series of updated…
HeartBeam Announces Early Completion of HEADSTART-ACS Enrollment in Largest Heart Attack Detection Study Using Its Technology
HeartBeam Completes Enrollment in 486-Patient HEADSTART-ACS Study Ahead of Schedule to Advance 3D ECG Heart Attack Detection Technology HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac…
AngioDynamics Announces DIRECT Study Results Publication and New Category I CPT Code for Pancreatic IRE
AngioDynamics Reports Positive DIRECT Study Results for NanoKnife IRE in Pancreatic Cancer and Announces New CPT Code for 2027 AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring…
Shionogi Presents IDWeek 2026 U.S. Real-World Data Showing Improved Outcomes with Early Fetroja®/Fetcroja® Treatment in Respiratory Infections
Shionogi to Present New Fetroja®/Fetcroja® Data at IDWeek 2026 Highlighting Early Treatment Outcomes and Activity Against Drug-Resistant Gram-Negative Bacteria Shionogi & Co., Ltd., headquartered in Osaka, Japan, and led by…
Savillex Expands Bioprocessing Portfolio with Entegris Life Sciences Acquisition
Savillex Completes Acquisition of Entegris Life Sciences Fluid Management Business to Expand Single-Use Bioprocessing Portfolio Savillex, LLC, a leading provider of high-purity fluid handling solutions for life sciences and laboratory…
Cosette Pharmaceuticals Secures FDA Approval for EVOXAC® Oral Solution, Marking First NDA Approval
Cosette Pharmaceuticals Receives FDA Approval for EVOXAC® Oral Solution to Treat Dry Mouth in Adults With Sjögren’s Disease Cosette Pharmaceuticals, Inc., a U.S.-based specialty pharmaceutical company, has announced that the…
Bionyra Pharma Reports Positive Interim Phase 1 Results for Long-Acting Anti-TL1A Antibody BYN-002
Bionyra Pharma Reports Positive Interim Phase 1 Results for Long-Acting Anti-TL1A Antibody BYN-002 Bionyra Pharma, a clinical-stage biopharmaceutical company developing next-generation biologics designed to harness multi-targeted biology for immune-mediated inflammatory…
Parse Biosciences Launches Evercode MAX to Expand Single-Cell Profiling Capacity and Flexibility
Parse Biosciences Launches Evercode MAX to Expand Single-Cell Sequencing Capacity and Reduce Research Costs Parse Biosciences, a leading provider of scalable and accessible single-cell sequencing technologies and a QIAGEN company,…
Algia Pharma Reports Positive IND-Enabling Study Results for AlgiaPak® Non-Opioid Acute Pain Treatment
Algia Pharma Completes IND-Enabling Toxicology Study for AlgiaPak, Advancing Non-Opioid Acute Pain Treatment Toward Clinical Trials Algia Pharma, LLC has announced the successful completion of an Investigational New Drug (IND)-enabling…
Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter to Halve Treatment Time
Johnson & Johnson Launches Shockwave C2 Aero Fly Coronary IVL Catheter to Cut Treatment Time in Half Johnson & Johnson (NYSE: JNJ) has announced the U.S. launch of its Shockwave…
Orogen Therapeutics Selects Two Development Candidates for Immune Diseases, Targeting IL-17 and JAK1/TYK2
Orogen Therapeutics Selects ORO-110 and ORO-210 Development Candidates for Inflammatory Diseases Orogen Therapeutics, Inc. (“Orogen” or the “Company”) announced the selection of two development candidates, ORO-110 and ORO-210, as potential…
Neurogene to Present Key Differentiators of NGN-401 for Rett Syndrome at ESGCT 33rd Annual Congress
Neurogene to Present New NGN-401 Gene Therapy Data for Rett Syndrome at ESGCT 2026 Neurogene Inc., a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases, announced…